What Is a CTPA Scan and What Does It Diagnose?

A CTPA, or computed tomography pulmonary angiography, is a specialized CT scan of the chest designed primarily to detect blood clots in the arteries of the lungs, a condition known as pulmonary embolism (PE). It works by injecting iodine-based contrast dye into a vein and timing the scan so that the dye highlights the pulmonary arteries at peak concentration, making even small clots visible as dark spots against the bright contrast. While PE is the headline diagnosis, a CTPA frequently reveals other chest conditions that explain the patient’s symptoms, from pneumonia to heart problems, making it one of the most information-rich emergency imaging tests available.

How the Scan Actually Works

You lie on the CT table with an intravenous line, usually placed in a vein at the inside of your elbow. A power injector pushes contrast dye through the line at a fast rate, typically around 5 milliliters per second, followed by a saline flush to push the remaining contrast toward your heart and lungs.¹ The total volume of contrast is usually between 60 and 75 milliliters, and the entire injection takes roughly 12 to 15 seconds.

Timing is everything. The scanner needs to capture images during the brief window when contrast fills the pulmonary arteries at peak concentration. To nail this, most protocols use a technique called bolus tracking: the scanner takes rapid low-dose monitoring images of the main pulmonary artery after injection begins, and when the contrast density in that artery crosses a set threshold, the full scan fires automatically.² You will be asked to take a breath in and hold it for a few seconds while the scanner acquires images of your entire chest. The whole process, from contrast injection to completed scan, takes well under a minute.

The Primary Target Is Pulmonary Embolism

PE happens when a blood clot, usually originating in a deep leg vein, breaks free and lodges in one or more pulmonary arteries. This can restrict blood flow to part of the lung, cause sudden chest pain and shortness of breath, and in severe cases become life-threatening. CTPA is considered the first-choice imaging test for diagnosing PE because of its wide availability, speed, and high accuracy for both confirming and ruling out the condition.³

On the images, a clot appears as a filling defect: a dark area within the bright contrast-filled artery. In acute PE, these defects typically have sharp borders against the surrounding contrast. A clot that partially blocks an artery often sits in the center of the vessel, while one pressed against the wall forms a sharp angle with it.⁴ When a clot completely blocks an artery, the vessel downstream may look enlarged compared to its counterpart on the other side. Radiologists use these visual patterns to distinguish acute PE from chronic clots, which tend to hug the vessel wall and may partially calcify over time.

Gauging Severity Beyond the Clot Itself

Finding a clot is only half the story. A CTPA can also tell doctors how much strain the clot is putting on the heart, which directly influences treatment decisions. When a large clot or multiple clots block a significant portion of pulmonary blood flow, pressure builds in the right side of the heart. The scan can reveal this in several ways: the right ventricle may appear dilated relative to the left ventricle, the wall between the two ventricles may bow toward the left side, contrast dye may reflux backward into the large vein entering the heart, and the main pulmonary artery may look wider than the adjacent aorta.⁵

A commonly used marker is the ratio of the right ventricle’s diameter to the left ventricle’s diameter. When that ratio reaches 0.9 or above on CT, it is generally flagged as evidence of right heart strain.⁶ This matters because patients with right heart strain from PE are at higher risk of deterioration and may need more aggressive treatment, including clot-busting drugs or catheter-based procedures. Research has shown that right ventricular dysfunction visible on CT, along with the central location of clots, can predict PE-related mortality in both stable and unstable patients.³

It is worth noting that there is not always perfect agreement between what CT shows and what an echocardiogram (ultrasound of the heart) shows regarding right heart strain. One study found low concordance between the two methods in identifying right ventricular strain in PE patients.⁷ Each test measures slightly different things, so doctors often use both when the clinical picture is unclear.

What Else a CTPA Can Diagnose

Many people sent for a CTPA turn out not to have PE. The positive rate hovers around 15% in some populations, meaning the majority of scans rule PE out rather than confirm it.⁸ But that does not make the scan a waste. Because CTPA captures detailed images of the entire chest, it frequently identifies other conditions that explain the patient’s symptoms. In one study, physicians had already suspected an alternative diagnosis before the scan in nearly half of cases, with pneumonia, fluid around the lungs, and tumor progression among the most common suspects.⁹

Even when neither PE nor the suspected alternative is found, CTPA routinely turns up incidental findings. One study found an average of three incidental findings per patient. The most common clinically urgent findings included cardiomegaly and aortic aneurysm; less urgent but still relevant findings included pleural effusion and pneumonia; and the most common benign findings were lung structural changes and thoracic bone abnormalities.¹⁰ In orthopedic patients evaluated after surgery, over half had atelectasis (collapsed portions of the lung), and roughly a third had pleural effusions, regardless of whether PE was present.¹¹ So even a “negative” CTPA may identify treatable problems or flag issues that need follow-up.

Not Everyone Needs a CTPA

Because CTPA involves radiation and contrast dye, it should not be used reflexively. Clinical decision tools exist specifically to reduce unnecessary scans. The general approach is to first estimate the probability of PE using a scoring system (the Wells score is the most widely used), then check a blood test called D-dimer. A low clinical probability combined with a low D-dimer can safely rule out PE without any imaging at all.

Refined approaches have improved this triage further. One study proposed a tiered decision rule: if D-dimer is below 500, PE can be excluded regardless of other clinical features; if D-dimer is between 500 and 1,000, a scan is only needed when the clinical picture specifically points toward PE or the patient has signs like deep vein thrombosis or coughing up blood; and if D-dimer is 1,000 or above, the patient should go straight to CTPA.¹²

Despite these tools, overuse remains a real issue. A retrospective analysis at one hospital found that only about 15% of CTPAs actually confirmed PE. Among patients under 50 who scored zero on a rule-out criteria checklist, nearly half still underwent imaging, and among older patients whose age-adjusted D-dimer was normal, every single scan came back negative.¹³ A structured diagnostic strategy in one middle-income country setting showed that applying clinical rules before ordering scans could have reduced CTPA costs by roughly a third for the cohort studied.¹⁴ The takeaway: if your doctor orders a D-dimer before a CTPA, that is good practice, not a delay in care.

Radiation Dose in Perspective

A common concern is how much radiation a CTPA delivers. Modern scanners have pushed the dose down substantially. One study found a mean radiation dose of about 5.5 millisieverts (mSv), which is roughly 1.8 times the average annual background radiation a person gets just from living in the United States. Older scanners delivered closer to 9 mSv, so the trend is clearly downward as technology improves.¹⁵

To put that in perspective, a CTPA delivers more radiation than a standard chest X-ray but less than many abdominal CT scans. For a single scan in a person with genuine concern for PE, the risk from radiation is extremely small compared to the risk of a missed clot. The concern becomes more relevant when patients need repeated imaging or when the scan was not clinically indicated in the first place, which circles back to why proper pre-test triage matters.

Contrast Dye and Kidney Risk

The iodine-based contrast used in CTPA has long been associated with concerns about kidney injury, sometimes called contrast-induced acute kidney injury. However, more recent evidence suggests the risk may be lower than traditionally feared. A large propensity-matched study compared patients who received contrast for CTPA against matched patients who did not. About 4.5% of contrast-exposed patients developed acute kidney injury compared to 3.4% of unexposed patients, a difference that was not statistically significant.¹⁶ In other words, much of the kidney injury seen after contrast administration may be caused by the underlying illness rather than the dye itself.

That said, certain groups are at higher risk. In elderly patients over 65, one study found a kidney injury rate of about 7% after CTPA, with diabetes being the strongest predictor of who developed problems.¹⁷ For patients with already impaired kidneys or diabetes, doctors may take extra precautions such as pre-hydration with intravenous fluids. But in an emergency where PE is a real possibility, the benefit of the scan almost always outweighs the kidney risk.

CTPA During Pregnancy

Pregnant women face a genuinely elevated risk of PE because pregnancy itself increases blood clot formation. At the same time, both radiation exposure and contrast dye raise legitimate safety questions for the developing fetus. The good news is that the fetal radiation dose from a CTPA is small. One study measuring doses across multiple scanners found that using the latest protocols decreased the effective dose for non-pregnant women by about 69%, and optimizing the scan length in pregnant women reduced the fetal dose by 76 to 83% without missing any cases of PE.¹⁸

One counterintuitive finding: placing a lead shield over a pregnant patient’s abdomen during CTPA can actually increase the radiation dose, not decrease it. A phantom study showed that shielding caused the scanner’s automatic exposure control system to compensate by cranking up the radiation output, resulting in a 47% higher effective dose to the patient compared to scanning without the shield.¹⁹ The fetal dose was also higher with shielding. This is why many radiology departments have moved away from routine abdominal shielding during CT, as modern scanners use automatic dose modulation that shielding can interfere with.

Optimized low-dose CTPA protocols for pregnancy are actively being validated. The OPTICA study, a prospective multicenter trial, is designed to confirm that these optimized protocols can safely rule out PE while minimizing both radiation and contrast exposure in pregnant patients.²⁰

CTPA Versus the V/Q Scan

The main alternative to CTPA for diagnosing PE is a ventilation-perfusion (V/Q) scan, which uses inhaled and injected radioactive tracers to look for mismatches between airflow and blood flow in the lungs. A randomized trial comparing the two found that CTPA was not inferior to V/Q scanning for ruling out PE, but it did detect significantly more cases of PE.²¹ That raises a nuanced question: are the extra cases detected by CTPA clinically meaningful clots, or are some of them tiny subsegmental emboli that might not need treatment? This debate is still ongoing in the field.

V/Q scanning has some practical advantages in specific situations. It delivers less radiation to the breast tissue (relevant for younger women), avoids iodinated contrast entirely (useful for patients with severe contrast allergies or very poor kidney function), and is the preferred screening test for chronic thromboembolic pulmonary hypertension, a long-term complication that develops in roughly 3% of PE survivors when clots fail to resolve completely.²² However, V/Q scans produce indeterminate results more often than CTPA and cannot provide the alternative diagnoses that CTPA can. In practice, CTPA dominates emergency evaluation because of speed, availability, and diagnostic breadth.

Dual-Energy CT and AI Triage

Standard CTPA shows the physical presence of a clot, but newer dual-energy CT technology adds a functional layer. By acquiring images at two different energy levels simultaneously, the scanner can generate iodine maps that show where blood is actually flowing in the lung tissue. Areas downstream of a clot will appear as perfusion defects on these maps even if the clot itself is small or hard to see on conventional images.²³

In a study of over 1,100 CT angiograms, reviewing the dual-energy iodine maps led to a new diagnosis of PE in about 1% of cases that would otherwise have been missed on standard images alone, with most of the newly detected clots located in smaller segmental and subsegmental arteries.²⁴ This technology is also being explored for chronic disease. Researchers have developed AI-driven tools that automatically quantify lung perfusion on dual-energy CTPA to evaluate patients with chronic clot-related changes in their pulmonary arteries.²⁵

AI is also making inroads in standard CTPA interpretation. Deep learning algorithms trained on thousands of scans can flag studies likely to be positive for PE, potentially allowing radiologists to prioritize urgent reads. A systematic review of these systems concluded that deep learning can serve as a reliable second reader for immediate interpretation and prioritization, with the potential to reduce the time between scan and diagnosis.²⁶ In busy emergency departments where radiologists may be reading many studies simultaneously, this kind of automated triage could mean faster treatment for patients with large, dangerous clots.

When Clots Do Not Fully Resolve

Most people who survive an acute PE recover fully as the clot dissolves over weeks to months with anticoagulation therapy. But in a small fraction of patients, the clot organizes into scar-like tissue that permanently narrows or blocks pulmonary arteries, eventually leading to chronic thromboembolic pulmonary hypertension (CTEPH). Estimates put the incidence of CTEPH at approximately 3% after acute PE.²² Symptoms are insidious, often appearing months or years later as progressive shortness of breath with exertion.

CTPA plays an important but secondary role in CTEPH evaluation. The V/Q scan remains the preferred screening tool because it is more sensitive for detecting the patchy blood-flow deficits that characterize chronic disease. However, once CTEPH is suspected, CT imaging helps confirm the diagnosis by showing the chronic clot material, thickened vessel walls, and the pattern of mosaic lung perfusion. Advanced CT techniques, including dual-energy perfusion mapping, are expanding the role of CT in both detecting and quantifying the severity of CTEPH. For patients who go on to surgical treatment (a procedure called pulmonary endarterectomy, in which the organized clot material is physically peeled out of the arteries), CT provides critical roadmapping for the surgeon.